Investors focused on the Medical space have likely heard of AEterna Zentaris (AEZS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of AEZS and the rest of the Medical group's stocks.
AEterna Zentaris is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AEZS is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for AEZS's full-year earnings has moved 780% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, AEZS has returned 63.98% so far this year. Meanwhile, stocks in the Medical group have gained about 6.25% on average. As we can see, AEterna Zentaris is performing better than its sector in the calendar year.
Looking more specifically, AEZS belongs to the Medical - Biomedical and Genetics industry, which includes 341 individual stocks and currently sits at #75 in the Zacks Industry Rank. This group has lost an average of 10.97% so far this year, so AEZS is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to AEZS as it looks to continue its solid performance.